The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the recent discoveries in clinical trials for acute myeloid leukemia?
Gail Roboz
September 17, 2020
During Blood Cancer Awareness Month, Know AML spoke to Gail Roboz, a world-leading doctor in acute myeloid leukemia who is based at Weill Cornell Medicine, New York, US. We asked, "Have there been any ground-breaking discoveries recently with clinical trials in acute myeloid leukemia?" In this video, Gail explains that there have been several recent ground-breaking clinical trials, and focuses on those involving targeted agents to IDH1/2 mutations, FLT3 inhibitors, venetoclax, and the recent U.S. Food and Drug Administration (FDA) approval for CC-486 in acute myeloid leukemia maintenance.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
